AUTHORS
Ragini Vuppugalla, Carlos Sepulveda2, Dimple Patel3, Pooya Aavani4, Matthew W Hruska5, Douglas Marsteller6
AFFILIATIONS
1 Kyowa Kirin, Inc., Princeton, New Jersey, United States
2 Kyowa Kirin, Inc., Princeton, New Jersey, United States
3 Kyowa Kirin, Inc., Princeton, New Jersey, United States
4 Kyowa Kirin, Inc., Princeton, New Jersey, United States
5 Kyowa Kirin, Inc., Princeton, New Jersey, United States
6 Kyowa Kirin, Inc., Princeton, New Jersey, United States
ABSTRACT
Introduction
Mogamulizumab, an anti-CCR4 monoclonal antibody, is approved for the treatment of adult patients with mycosis fungoides (MF) or Sézary syndrome (SS) after ≥1 prior systemic therapy. The approved dosing regimen, after weekly 1 mg/kg intravenous (IV) infusions during the first 4-week loading cycle, is 1 mg/kg IV infusion every 2 weeks (Q2W) during each subsequent 4-week cycle (1 mg/kg Q2W). An alternate dosing regimen of 2 mg/kg every 4 weeks (2 mg/kg Q4W) was explored after the first 4-week loading cycle, to reduce the number of required clinic visits. This analysis evaluated population pharmacokinetics (PPK) and exposure–response (ER) relationships for efficacy and safety to support the 2 mg/kg Q4W regimen.
Methods
The integrated PPK analysis included 816 participants (median age, 63 years [range, 19–101 years]; 57.0% male) from 12 mogamulizumab monotherapy or combination studies spanning doses of 0.01–3 mg/kg and QW, Q2W, Q3W, and Q4W regimens. ER analyses of efficacy (overall response rate [ORR], progression-free survival [PFS]) and safety included 216 participants (MF, 60.6%; SS, 39.4%) from 2 studies and 473 participants from 8 studies, respectively.
PPK model development evaluated structural, interindividual-variability, residual-error, and covariate components. Average, maximum, and minimum mogamulizumab concentrations (Cavg, Cmax, and Cmin) at Cycle 2 and steady state were predicted and compared for mogamulizumab 2 mg/kg Q4W and 1 mg/kg Q2W. ER relationships between ORR or PFS and mogamulizumab exposure using Cmin at Cycle 2, and time to first event for 4 groups of treatment-emergent adverse events of special interest (TEAESI) and mogamulizumab exposure using Cmax at Cycle 2 were evaluated for 2 mg/kg Q4W and 1 mg/kg Q2W. The TEAESI groups were Grade 3/4 adverse events (AEs), infections, skin/subcutaneous rash events, and immune-mediated events. Supportive pharmacodynamic assessments observed in 2 mogamulizumab studies of 2 mg/kg Q4W and 1 mg/kg Q2W evaluated changes in circulating malignant T cells.
Results
Mogamulizumab pharmacokinetics was adequately described using a 2-compartment model with linear clearance, interindividual variability on clearance and central volume, and a combined proportional and additive residual-error model. The model accounted for clinically relevant effects of body weight, albumin, sex, race, and hepatic function. Steady state was achieved by approximately Cycle 4 for 2 mg/kg Q4W and 1 mg/kg Q2W.
Compared with 1 mg/kg Q2W, predicted exposure for 2 mg/kg Q4W at Cycle 2 and steady state, respectively, resulted in a 46.4% and 46.7% higher Cmax and a 23.5% and 34.7% lower Cmin. Also, compared with 1 mg/kg Q2W, predicted Cavg for 2 mg/kg Q4W was 16.1% higher at Cycle 2 and was essentially unchanged at steady state (0.2% higher).
A linear logistic regression model identified a positive exposure–ORR relationship, with cutaneous T-cell lymphoma subtype retained in the final model. Model-predicted ORR for 1 mg/kg Q2W vs 2 mg/kg Q4W was 21.3% (95% uncertainty interval [UI], 15.5%–28.4%) vs 18.3% (95% UI, 13.2%–25.1%) in participants with MF and 41.1% (95% UI, 31.6%–50.8%) vs 36.3% (95% UI, 27.7%–45.8%) in participants with SS. The 95% UIs overlapped between regimens within each subtype. No exposure–PFS relationship was identified; predicted 12-month PFS was comparable for 1 mg/kg Q2W vs 2 mg/kg Q4W in participants with MF (33.9% vs 32.1%) and SS (49.4% vs 47.9%).
Cox proportional hazards models described time to each TEAESI. Applying the fitted models to regimen-specific simulated exposures yielded comparable model-predicted 6-month probabilities for 1 mg/kg Q2W vs 2 mg/kg Q4W: Grade 3/4 AEs (48.7% vs 48.4%), infections (36.2% vs 35.3%), skin/subcutaneous rash events (44.5% vs 47.2%), and immune-mediated events (25.5% vs 24.7%). Supportive pharmacodynamic assessments showed comparable reductions in circulating malignant T cells between the two dosing regimens.
Conclusions
PPK analyses suggest the alternate mogamulizumab dosing regimen (2 mg/kg Q4W) would result in mogamulizumab exposures that are efficacious and tolerable. The ER analyses demonstrated comparable ORR, PFS, and TEAESI for 2 mg/kg Q4W and 1 mg/kg Q2W (approved dosing). These results support use of the alternate mogamulizumab dosing regimen as a treatment for certain patients with relapsed/refractory MF or SS who may have logistical challenges in receiving Q2W dosing.
Funding
The work was funded by Kyowa Kirin, Inc.
DISCLOSURES
Ragini Vuppugalla: Kyowa Kirin Inc - Current Employment